Trial Profile
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms VITALITY-ALS
- Sponsors Cytokinetics
- 29 Nov 2023 According to Cytokinetics media release, data from this study will be presented at the 34th International Symposium
- 04 Aug 2022 According to a Cytokinetics media release, the company announced the release of pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from this trial.
- 10 Dec 2018 Sub-group analyses data of the impact of time from diagnosis on the efficacy of tirasemtiv published in a Cytokinetics media release.